Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)

Hum Reprod. 2004 Jan;19(1):41-7. doi: 10.1093/humrep/deh098.

Abstract

Since the 1990 NIH-sponsored conference on polycystic ovary syndrome (PCOS), it has become appreciated that the syndrome encompasses a broader spectrum of signs and symptoms of ovarian dysfunction than those defined by the original diagnostic criteria. The 2003 Rotterdam consensus workshop concluded that PCOS is a syndrome of ovarian dysfunction along with the cardinal features hyperandrogenism and polycystic ovary (PCO) morphology. PCOS remains a syndrome and, as such, no single diagnostic criterion (such as hyperandrogenism or PCO) is sufficient for clinical diagnosis. Its clinical manifestations may include: menstrual irregularities, signs of androgen excess, and obesity. Insulin resistance and elevated serum LH levels are also common features in PCOS. PCOS is associated with an increased risk of type 2 diabetes and cardiovascular events.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Clinical Trials as Topic
  • Consensus Development Conferences as Topic
  • Consensus Development Conferences, NIH as Topic
  • Female
  • Humans
  • Hyperandrogenism / complications
  • Insulin Resistance
  • Luteinizing Hormone / blood
  • Polycystic Ovary Syndrome / blood
  • Polycystic Ovary Syndrome / complications*
  • Polycystic Ovary Syndrome / diagnosis*
  • Polycystic Ovary Syndrome / pathology
  • Risk Factors
  • United States

Substances

  • Luteinizing Hormone